{
    "nctId": "NCT01080170",
    "briefTitle": "The Effect of Aromatase Inhibitors on Cardiovascular Risk Factors in Women With Breast Cancer",
    "officialTitle": "N/A",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "Body Composition",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Ambulatory women (aged 60-75), with a new diagnosis of nonmetastatic, hormone-receptor positive breast cancer, having undergone lumpectomy. They will not need chemotherapy and will have been prescribed but not yet started anastrazole. All will need a course of radiation therapy as part of usual care. Participants are instructed not to change their physical activity or eating habits over the period of the study.\n\nComparisons are:\n\n* Identical to the cases except they are hormone-receptor negative and don't need hormonal therapy.\n* Healthy controls.\n\nExclusion Criteria:\n\n* Nicotine usage\n* Metastatic breast cancer\n* Need for chemotherapy\n* AI other than anastrazole\n* Usage of steroids (equivalent of equal then or more than 7.5 mg prednisone x 3 months)\n* Clinically significant abnormality of thyroid function\n* Treatment with gonadal hormone replacement therapy within last 3 years\n* Status post unilateral/bilateral surgical oophorectomy\n* Having experienced a medical event, which may confound study outcomes \\[e.g. heart attack, stroke, cancer (metastatic or newly diagnosed within last 5 years, except for non-melanoma skin cancer and breast), lupus, rheumatoid arthritis, chronic inflammatory disease\\]\n* Medication-dependent diabetes mellitus or hypercholesterolemia.\n* Gastric surgery\n* Weight loss medication (prescription or over the counter)",
    "sex": "FEMALE",
    "minimumAge": "60 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}